期刊文献+

华法林合并阿司匹林在门诊房颤患者中的应用

暂未订购
导出
摘要 目的结合心房颤动(简称房颤)门诊病例的临床特点,伴随疾病,治疗情况,血栓栓塞并发症的患病率和本地区抗凝治疗的低普及率及华法林低使用率,对2005年2月至2005年12月来我院门诊就诊的46例非瓣膜性房颤(NVAF)患者进行适当抗凝治疗并观察其临床效果以及探讨门诊给予华法林治疗的安全性。方法将该46例(NVAF)患者随机分为2组,进行治疗观察,即给予口服小剂量华法林合并阿司匹林治疗的23例,给予口服常规治疗方法剂量华法林治疗的23例,并随访6个月进行2组治疗效果和安全性比较。结果经用2组不同抗凝方法在门诊对患者进行治疗,国际标准比值(INR)达到1.5?2.5后,血栓栓塞事件较原有了显著下降。但常规方法治疗剂量华法林抗凝治疗后患者出现副作用较联合治疗组明显。结论华法林合并阿司匹林较单独使用华法林对降低心房颤动所致血栓栓塞事件的发生率更加安全有效,同时不失为一种患者易于接受的门诊治疗的方法,亦是普及抗凝治疗及提高房颤患者生存率的有效治疗措施之一。
作者 郭潇
出处 《甘肃科技》 2007年第5期192-193,183,共3页 Gansu Science and Technology
  • 相关文献

参考文献2

二级参考文献23

  • 1Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the
  • 2Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001,119(1 Suppl):8S-21S.
  • 3Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest, 2001,119(1 Suppl):108S-121S.
  • 4The stroke prevention in atrial fibrillation investigation. Bleeding during antithrombotic thearapy in patients with atrial fibrillation. Arch Intern Med, 1996, 156:409-416.
  • 5Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med, 1996,124:970-979.
  • 6Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med,1994,120:897-902.
  • 7Stroke prevention in atrial fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation Ⅲ randomized clinic trial. Lan
  • 8Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of reccurrent venous thromboembolism. N Engl J Med, 2003,348:1425-1434.
  • 9Bo os CJ, More RS.Anticoagulation for non-valvular atrial fibrillation-towards a new beginning with xime1agatran[J].Curr Control Trials Cardiovasc Med,2004,5 (1):3.
  • 10Lorenzoni R, Lazzeini G, Cocci F,et al. Short-term prevenion of thromboem bolic complications in patients with atrial fibrllation with aspirin plus clopid ogrel:the clopidogrel-aspirin atrial fibrillation(CLAAF) pilot study[J].Am He art J,2004,148(1):e6.

共引文献174

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部